Skip to main content
News

Gaithersburg’s Emergent BioSolutions manufactures Ebola vaccine candidate for clinical trials with GlaxoSmithKline – Washington Business Journal

By March 17, 2015No Comments
emergent-biosolution-logo

emergent-biosolution-logo

Emergent BioSolutions Inc. has manufactured a possible Ebola vaccine that could serve as the booster for GlaxoSmithKline’s frontrunner candidate in the international race to create an effective treatment for the deadly virus.

Gaithersburg-based Emergent (NYSE: EBS) produced a vaccine batch that will be used by Oxford University researchers in a Phase 1 clinical trial with GlaxoSmithKline’s Ebola candidate. GSK’s candidate uses a type of chimpanzee virus to deliver safe genetic material from the Zaire strain of Ebola, the strain responsible for the epidemic in West Africa. That drug candidate began clinical trials in Africa in January, Reuters reported.

{iframe}http://www.bizjournals.com/washington/blog/2015/03/emergent-biosciences-manufactures-possible-ebola.html?ana=e_du_pap&s=article_du&ed=2015-03-16&u=wjGEy67ABoSnsLErlc5ry0j5hx3&t=1426618737{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.